What is Leerink Partnrs' Estimate for CLDX FY2028 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Leerink Partnrs cut their FY2028 earnings per share estimates for Celldex Therapeutics in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceutical company will post earnings per share of $0.99 for the year, down from their prior forecast of $1.04. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Celldex Therapeutics' FY2029 earnings at $6.67 EPS.

A number of other equities research analysts have also recently commented on CLDX. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Celldex Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $62.25.

Celldex Therapeutics Price Performance

Shares of CLDX stock traded down $0.93 during mid-day trading on Thursday, hitting $21.54. 825,512 shares of the stock traded hands, compared to its average volume of 1,026,988. Celldex Therapeutics has a 52-week low of $21.18 and a 52-week high of $53.18. The stock has a market cap of $1.43 billion, a P/E ratio of -8.38 and a beta of 1.60. The stock's fifty day moving average is $25.13 and its two-hundred day moving average is $30.40.

Institutional Trading of Celldex Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its stake in shares of Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock valued at $314,190,000 after buying an additional 1,167,659 shares during the last quarter. Jennison Associates LLC grew its position in shares of Celldex Therapeutics by 32.0% in the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company's stock valued at $45,017,000 after purchasing an additional 321,325 shares in the last quarter. Emerald Advisers LLC raised its stake in Celldex Therapeutics by 129.9% during the third quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company's stock worth $15,506,000 after purchasing an additional 257,773 shares during the period. Fisher Asset Management LLC grew its position in Celldex Therapeutics by 210.6% in the third quarter. Fisher Asset Management LLC now owns 374,352 shares of the biopharmaceutical company's stock worth $12,724,000 after acquiring an additional 253,808 shares during the period. Finally, Readystate Asset Management LP purchased a new position in Celldex Therapeutics during the third quarter worth about $6,102,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.